Combinations including methocinnamox
AssigneeBoard of Regents, The University of Texas System
InventorCharles Patrick FRANCE
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for treating opioid use disorders, including opioid overdose with combinations including methocinnamox and at least one additional opioid modulators, for example opioid agonists, partial agonists, antagonists and allosteric modulators. The compositions and methods are also useful for treating alcohol use disorder, and other disorders associated with endogenous opioid production.
Claims73
A method of treating an opioid use disorder in a subject, comprising administering to the subject in need thereof an effective amount of methocinnamox, or a pharmaceutically acceptable salt thereof, in combination with at least one additional opioid receptor modulator.
A method for supporting opioid cessation in a subject in need thereof, comprising administering to the subject an effective amount of methocinnamox, or a pharmaceutically acceptable salt thereof, in combination with at least one additional opioid receptor modulator.
A method of treating an alcohol use disorder in a subject, comprising administering to the subject in need thereof an effective amount of methocinnamox, or a pharmaceutically acceptable salt thereof, in combination with at least one additional opioid receptor modulator.
A method for reducing alcohol consumption in a subject, comprising administering to the subject in need thereof an effective amount of methocinnamox, or a pharmaceutically acceptable salt thereof, in combination with at least one additional opioid receptor modulator.
A method for promoting alcohol use cessation in a subject, comprising administering to the subject in need thereof an effective amount of methocinnamox, or a pharmaceutically acceptable salt thereof, in combination with at least one additional opioid receptor modulator.
The method according to any of claims 1-52, wherein the additional opioid receptor modulator is administered enterally, parenterally, intranasally, vaginally, by inhalation, or a combination thereof.
The method according to any preceding claim, wherein the methocinnamox and additional opioid receptor modulator are administered in the same unit dose.
A pharmaceutical composition, comprising methocinnamox, or a pharmaceutically acceptable salt thereof, and at least one additional opioid receptor modulator.
A kit for the treatment of an opioid use disorder, comprising methocinnamox, or a pharmaceutically acceptable salt thereof, and at least one additional opioid receptor modulator.
Dependencies are inferred from the claim text.